Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4)
Moderate Confidence RCT ≤3 YearsOutcomes summary
Retatrutide (12 mg) achieved a mean weight loss of 28.7% (71.2 lbs) at 68 weeks compared to 2.1% for placebo. Participants also experienced a 75.8% reduction in WOMAC pain scores (4.5 points) vs. 35.1% for placebo. Secondary endpoints showed improvements in physical function and cardiovascular risk markers.
Limitations
Industry-sponsored topline results from press release; formal peer-reviewed publication pending. A new safety signal of dysesthesia (abnormal touch sensation) was reported in up to 20.9% of participants on the highest dose.
Notes
These are topline results from the first successful Phase 3 trial in the TRIUMPH registrational program. The trial specifically looked at the subset of patients with obesity and clinical knee osteoarthritis. The results demonstrate the highest weight reduction efficacy seen in a registrational trial to date for an anti-obesity medication.